Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multi-center Trial to Evaluate the Feasibility and Safety of Short-term Treatment With Subcutaneously Injected Certoparin (8000 U Anti-Xa Twice Daily) in Patients With Persistent Nonvalvular Atrial Fibrillation

NCT00171769 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00171769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00171769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multi-center Trial to Evaluate the Feasibility and Safety of Short-term Treatment With Subcutaneously Injected Certoparin (8000 U Anti-Xa Twice Daily) in Patients With Persistent Nonvalvular Atrial Fibrillation
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2005
Completion date
Not reported
Enrollment
200
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

persistent nonvalvular atrial fibrillation